Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Schmid
Hans-Peter
HP
Department of Urology, Kantonsspital, St. Gallen, Switzerland. hans-peter.schmid@kssg.ch
Engeler
Daniel S
DS